Correction

Correction: Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells

Yingying Shen[1,*], Xiaomei Ren[2,*], Ke Ding[2], Zhang Zhang[2], Deping Wang[2] and Jingxuan Pan[1,3,4]

[1]Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China

[2]Key Laboratory of Regenerative Biology and Institute of Chemical Biology, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

[3]State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China

[4]Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China

[*]These authors contributed equally to this work

Published:

This article has been corrected: In Figure 3C, both immunoblots for P-Bim-EL (Ser69) are accidental duplicates (the same blots are shown for both time-dependent and dose-dependent). The corrected Figure 3C, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2014; 5:10407–10420. https://doi.org/10.18632/oncotarget.2090

C



Figure 3: S116836 induces apoptosis in FIP1L1-PDGFRα-expressing cells. (**C**) Expression of apoptosis-related proteins was analyzed by Western blotting analysis.